comparemela.com

Latest Breaking News On - Biologics license application - Page 1 : comparemela.com

Opthea Announces Placement and Partially Underwritten

Opthea Announces Placement and Partially Underwritten
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

Australia
United-states
New-zealand
Melbourne
Victoria
American
Frederic-guerard
Fred-guerard
Vegfd-research
Opthea-limited
Bell-potter-securities
Investment-in-biotechnology-companies

Capricor Advances in DMD Therapy With Positive Study Data - Hims & Hers Health (NYSE:HIMS), Capricor Therapeutics (NASDAQ:CAPR)

Capricor Therapeutics (NASDAQ: CAPR), a biotechnology firm focused on innovative therapies for rare diseases, has announced favorable three-year results from the ongoing HOPE-2 open-label extension (OLE) study on CAP-1002 for Duchenne muscular dystrophy.

United-states
Cincinnati
Ohio
Cincinnati-children-hospital-medical-center
Hims-hers-health
Cincinnati-children
Hospital-medical-center
Biologics-license-application
Market-prospects
Mordor-intelligence
Zacks-rank

CHECKPOINT ALERT: Bragar Eagel & Squire, P.C. is Investigating Checkpoint Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

CHECKPOINT ALERT: Bragar Eagel & Squire, P.C. is Investigating Checkpoint Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New-york
United-states
California
South-carolina
Brandon-walker
Bragar-eagel-squire
Marion-passmore
Drug-administration
Nasdaq
Checkpoint-therapeutics-inc
Checkpoint-therapeutics
Class-period

Functional Improvement Seen With C1q Inhibitor in Guillain-Barré Syndrome

ANX005 is a C1q inhibitor that is administered intravenously and works by blocking the activation of classical complement pathway.

Bangladesh
Philippines
International-guillain-barr
Drug-administration
Research-council
Peripheral-nerve-society-annual-meeting-on
Medical-research-council
Douglas-love
Western-international-guillain-barr
Syndrome-outcomes-study
Biologics-license-application

Corporate Presentation: June 2024 - MarketScreener

NASDAQ: OTLK outlooktherapeutics.com Redefining the Standard of Carefor Ophthalmic Therapies Corporate.

United-kingdom
United-states
America
Outlook-therapeutics-inc
European-union
Regulatory-agency
Exchange-commission
Drug-administration
Outlook-therapeutics
Complete-response-letter
Biologics-license-application

vimarsana © 2020. All Rights Reserved.